日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study

根据同源重组缺陷状态分层的三阴性乳腺癌患者接受基于艾立布林的新辅助化疗的长期疗效：随机JBCRG-22研究的结果

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-026-07917-5
Masuda, Norikazu; Yasojima, Hiroyuki; Bando, Hiroko; Yamanaka, Takashi; Shigematsu, Hideo; Takahashi, Masato; Nagai, Shigenori E; Ito, Mitsuya; Aruga, Tomoyuki; Tokiwa, Mariko; Imoto, Shigeru; Nakamura, Rikiya; Ishiguro, Hiroshi; Kawabata, Hidetaka; Saji, Shigehira; Haga, Hironori; Morita, Satoshi; Toi, Masakazu
BCR
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Correction: Honda et al. Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype. Tomography 2022, 8, 1522-1533

更正：Honda 等人，《新辅助全身治疗后乳腺癌残留评估中超快速 MRI 的视觉评价：与亚型相关的初步研究》，《断层扫描》2022，8，1522-1533。

期刊:Tomography
影响因子:2.2
doi:10.3390/tomography12010006
Honda, Maya; Kataoka, Masako; Iima, Mami; Ota, Rie; Ohashi, Akane; Kishimoto, Ayami Ohno; Miyake, Kanae Kawai; Nickel, Marcel Dominik; Yamada, Yosuke; Toi, Masakazu; Nakamoto, Yuji
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

帕妥珠单抗再治疗人表皮生长因子受体2阳性局部晚期/转移性乳腺癌（PRECIOUS研究）：最终总生存期分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-24-01673
Yamamoto, Yutaka; Iwata, Hiroji; Saji, Shigehira; Takahashi, Masato; Yoshinami, Tetsuhiro; Ueno, Takayuki; Toyama, Tatsuya; Yamanaka, Takashi; Takano, Toshimi; Kashiwaba, Masahiro; Tsugawa, Koichiro; Hasegawa, Yoshie; Tamura, Kenji; Tada, Hiroshi; Hara, Fumikata; Fujisawa, Tomomi; Niikura, Naoki; Taira, Naruto; Morita, Satoshi; Toi, Masakazu; Ohno, Shinji; Masuda, Norikazu
肿瘤
肿瘤免疫
信号转导
乳腺癌
Human
发表日期：2025
文献求助 收藏

Erratum: Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

更正：帕妥珠单抗再治疗人表皮生长因子受体2阳性局部晚期/转移性乳腺癌（PRECIOUS研究）：最终总生存期分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-00722
Yamamoto, Yutaka; Iwata, Hiroji; Saji, Shigehira; Takahashi, Masato; Yoshinami, Tetsuhiro; Ueno, Takayuki; Toyama, Tatsuya; Yamanaka, Takashi; Takano, Toshimi; Kashiwaba, Masahiro; Tsugawa, Koichiro; Hasegawa, Yoshie; Tamura, Kenji; Tada, Hiroshi; Hara, Fumikata; Fujisawa, Tomomi; Niikura, Naoki; Taira, Naruto; Morita, Satoshi; Toi, Masakazu; Ohno, Shinji; Masuda, Norikazu
肿瘤
肿瘤免疫
信号转导
乳腺癌
Human
发表日期：2025
文献求助 收藏

Survival of patients with squamous cell carcinoma of the breast compared with invasive ductal carcinoma by biological subtype: A matched analysis of the Japanese national clinical database-breast cancer registry

根据生物学亚型比较乳腺鳞状细胞癌和浸润性导管癌患者的生存率：一项基于日本国家临床数据库-乳腺癌登记处的匹配分析

期刊:Breast
影响因子:7.9
doi:10.1016/j.breast.2025.104567
Ogita, Mami; Kumamaru, Hiraku; Kubo, Makoto; Kinukawa, Naoko; Niikura, Naoki; Saji, Shigehira; Toi, Masakazu
细胞生物学
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey

辅助S-1联合内分泌治疗ER阳性、HER2阴性原发性乳腺癌：POTENT试验后预后调查

期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-025-00832-w
Takada, Masahiro; Saji, Shigehira; Ueno, Takayuki; Masuda, Norikazu; Ishiguro, Hiroshi; Ishida, Takanori; Saeki, Toshiaki; Imoto, Shigeru; Ohno, Shinji; Iwata, Hiroji; Sugie, Tomoharu; Aogi, Kenjiro; Takayama, Shin; Sato, Nobuaki; Kai, Yuichiro; Kitada, Masahiro; Nakamura, Rikiya; Watanabe, Kenichi; Matsuyama, Yutaka; Toi, Masakazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis

BRCA1/2 和其他易感基因在接受内分泌治疗（含或不含帕博西尼）的高危激素受体阳性/人表皮生长因子受体 2 阴性乳腺癌患者中的作用：一项 PENELOPE-B 研究的二次分析

期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO-24-00742
Hahnen, Eric; Hauke, Jan; Gelmon, Karen; Marmé, Frederik; Ernst, Corinna; Martin, Miguel; Untch, Michael; Bonnefoi, Hervé; Knudsen, Erik; Im, Seock-Ah; DeMichele, Angela; Van't Veer, Laura; Kim, Sung-Bae; Bear, Harry; McCarthy, Nicole; Rhiem, Kerstin; Turner, Nicholas; Witkiewicz, Agnieszka; Rojo, Federico; Filipits, Martin; Martin, Lesley-Ann; Fasching, Peter A; Schem, Christian; Becker, Kerstin; García-Sáenz, José A; Kelly, Catherine M; Reimer, Toralf; Toi, Masakazu; Rugo, Hope S; Denkert, Carsten; Gnant, Michael; Makris, Andreas; Liu, Yuan; Valota, Olga; Felder, Bärbel; Weber, Karsten; Nekljudova, Valentina; Loibl, Sibylle
肿瘤
肿瘤免疫
信号转导
乳腺癌
BRCA1
Human
免疫/内分泌
发表日期：2025
文献求助 收藏

Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer

帕博西尼用于可手术、激素受体阳性乳腺癌女性患者的新辅助治疗

期刊:Endocrine-Related Cancer
影响因子:4.6
doi:10.1530/ERC-24-0353
Ueno, Takayuki; Chow, Louis W C; Han, Wonshik; Huang, Chiun Sheng; Mann, G Bruce; Morita, Satoshi; Haga, Hironori; Fakhrejahani, Elham; Kobayashi, Takayuki; Bando, Hiroko; Inoue, Kenichi; Tokiwa, Mariko; Suwa, Hirofumi; Aruga, Tomoyuki; Minamiguchi, Sachiko; Yamada, Yosuke; Tanabe, Yuko; Takada, Masahiro; Yamashita, Toshinari; Iwata, Hiroji; Chung, Chi-Feng; Takahara, Sachiko; Tokunaga, Eriko; Imoto, Shigeru; Lee, Eun Sook; Sagara, Yasuaki; Kim, Jee Hyun; DeBoer, Richard H; Kim, Hyun-Ah; Lai, Hung Wen; Hou, Ming Feng; White, Michelle; Umeyama, Yoshiko; Toi, Masakazu
肿瘤
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏

Polydactyly bone marrow-derived mesenchymal stem cell-conditioned medium can prevent cartilage degeneration and alleviate knee pain in a rat model of osteoarthritis

多指畸形骨髓间充质干细胞条件培养基可以预防骨关节炎大鼠模型中的软骨退化并缓解膝关节疼痛

期刊:Regenerative Therapy
影响因子:3.5
doi:10.1016/j.reth.2025.07.010
Akai, Shunsuke; Iseki, Tomoya; Nakao, Yoshitaka; Toi, Masakazu; Yamaura, Tetsuto; Takeuchi, Shunsuke; Tachibana, Toshiya
发育与干细胞
细胞生物学
Rat
干细胞
关节炎
发表日期：2025
文献求助 收藏

Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial

Capivasertib 和 fulvestrant 用于 HR 阳性/HER2 阴性晚期乳腺癌患者：CAPItello-291 III 期试验中日本患者亚组分析

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-024-01640-z
Tokunaga, Eriko; Iwata, Hiroji; Itoh, Mitsuya; Taira, Tetsuhiko; Toyama, Tatsuya; Mizuno, Toshiro; Osaki, Akihiko; Yanagita, Yasuhiro; Nakamura, Seigo; Nakamura, Rikiya; Sambe, Tomoko; Ozaki, Toshiaki; Schiavon, Gaia; Howell, Sacha J; Toi, Masakazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏